Activity
Mon
Wed
Fri
Sun
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
What is this?
Less
More

Memberships

The Iron Forge Brotherhood

41.1k members • Free

Heather Dawn Research Wellness

3.7k members • Free

Orion Peptides

295 members • Free

Peptides & Biohacking Hub

1.7k members • Free

HolisticAmerican-HealthAcademy

3.6k members • Free

2 contributions to Orion Peptides
GLP-1 Drugs and Cancer: Could These Medications Help Slow Cancer Progression?
A special thank you to Orion Peptides for supporting independent peptide education. If you're purchasing research peptides, you can save 15% with code PARKER15. A New Cancer Study Is Turning Heads For years, GLP-1 receptor agonists have been studied primarily for two reasons: - Blood sugar control - Weight loss But researchers are beginning to ask a much bigger question: Could these medications have benefits that extend far beyond metabolism? A new study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has sparked considerable interest after reporting that patients taking GLP-1 receptor agonists were less likely to develop metastatic disease across several common cancers. The findings are intriguing—but they also require careful interpretation. Here's what researchers found, why scientists are excited, and why it's far too early to consider GLP-1 drugs as cancer treatments. What Did the Study Investigate? Researchers analyzed medical records from more than 10,000 patients diagnosed with Stage I, II, or III solid tumors. The cancers included: - Breast cancer - Colorectal cancer - Liver cancer - Lung cancer - Pancreatic cancer - Prostate cancer - Kidney cancer Every patient began taking a GLP-1 receptor agonist after their cancer diagnosis. Researchers then matched these patients with similar individuals who instead started a DPP-4 inhibitor, another class of diabetes medication commonly used to manage blood sugar. The goal was simple: Compare how often cancer progressed to metastatic (Stage IV) disease between the two groups. What Did Researchers Find? The results surprised many investigators. Across nearly every cancer studied, patients receiving GLP-1 medications experienced lower rates of metastatic progression than patients taking DPP-4 inhibitors. The strongest findings occurred in: Non-Small Cell Lung Cancer Patients receiving GLP-1 therapy were approximately 50% less likely to progress to metastatic disease.
0 likes • 2d
the black box warning on at least 2 say thyroid cancer in 1-3 yes. and arthritis.
0 likes • 1d
and just today blindness. believe me I am all about peptides but the glps scare me. the food not digesting. urgh.
🛑 Community Rules: Read Before Posting 🛑
Welcome to the team! To keep this space free, educational, and safe for everyone, please read and respect the following guidelines. We are here to research and learn, not to spam or endanger others. 1. NO Selling or Solicitation (Zero Tolerance)🚫 : - Do not use this group to sell your own products, promote your own affiliate links, or push "Underground Lab" (UGL) items. - Any member caught sliding into DMs to sell substances or unverified services will be banned immediately. 2. This is NOT Medical Advice ⚠️ - While I am a professional Biohacking Coach and Trainer, I am not a doctor, and neither are most members here. - Everything shared here is for informational, educational, and research purposes only. - Do not prescribe protocols to others as absolute medical fact. - Always consult with a qualified medical professional (like our partners at Optimal Clinic) before starting any new therapy. 3. Research & "Bro-Science" 🧪 - We love new experiments, but please distinguish between anecdotal experience (what worked for you) and scientific fact. - If you make a bold claim, try to back it up with a source or clearly state that it is just your personal experience. - Help us fight misinformation by calling out bad data respectfully. 4. Respect & Professionalism 🤝 - We are navigating a complex industry together. Treat fellow researchers with respect. - No flaming, harassment, or bullying. - Disagreements are fine; disrespect is not. 5. Privacy Matters 🔒 - Do not post private personal information (addresses, phone numbers, etc.) or sensitive payment details regarding vendors publicly. Keep the feed clean and safe. 🔒
0 likes • 2d
Agree
1-2 of 2
Jeff Horton
1
5points to level up
@jeff-horton-3780
hey..whats up?

Active 14h ago
Joined Jul 10, 2026